Oncology & Cancer
Hereditary cancer is more common than you might think
Cancer touches nearly every Australian, with 1 in 2 people facing a diagnosis by age 85.
Sep 16, 2024
0
1
Cancer
Obstetrics & gynaecology
Gynecological cancers: Immunotherapy and targeted drug appear beneficial in group of women with early-stage disease
Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human ...
Sep 16, 2024
0
0
Oncology & Cancer
Studies show immunotherapy improves long-term survival in growing number of cancers
Immunotherapy, which works by enabling the body's immune system to recognize and destroy cancer cells improves long-term overall survival in patients with advanced melanoma in results from large international studies reported ...
Sep 16, 2024
0
0
Diseases, Conditions, Syndromes
Gasping for air: Staggering cost of breathlessness in Australia revealed
Breathlessness drains at least $12B from the Australian economy every year in direct health and productivity costs, and people living with the condition are more likely to be unemployed and have diminished quality of life, ...
Sep 16, 2024
0
0
Oncology & Cancer
Study reveals how mutant p53 protein converts other proteins into cancer drivers
Research from the Federal University of Rio de Janeiro (UFRJ) and the National Institute of Science and Technology for Structural Biology and Bioimaging (INBEB) in Brazil has uncovered a critical mechanism by which mutations ...
Sep 16, 2024
0
60
Oncology & Cancer
Study offers hope of a new treatment for rare endometrial cancer
A team of researchers at the University of Alberta has found that digoxin, a drug widely used to treat congestive heart failure, is an effective therapy for a rare and aggressive form of endometrial cancer.
Sep 16, 2024
0
0
Oncology & Cancer
High-dose vitamin D3 does not provide benefit for metastatic colorectal cancer, clinical trial shows
SOLARIS (Alliance A021703), a multicenter, double-blind, randomized Phase III clinical trial led by Dana-Farber Cancer Institute researchers and conducted across several hundred cancer centers in the U.S. tested the addition ...
Sep 16, 2024
0
0
Oncology & Cancer
Waiting is the hardest part: Medical field should address uncertainty for cancer patients under active surveillance
Patients with low-risk cancers undergoing active surveillance face a favorable long-term prognosis. David Haggstrom, M.D., MAS, makes the case that it's time for the medical field to help manage the anxiety caused by waiting.
Sep 16, 2024
0
0
Oncology & Cancer
Study links neighborhood environment to prostate cancer risk in men with West African genetic ancestry
According to a study led by researchers at the National Institutes of Health (NIH), West African genetic ancestry was associated with increased prostate cancer among men living in disadvantaged neighborhoods but not among ...
Sep 16, 2024
0
0
Oncology & Cancer
Immunotherapy shows promise for men with specific types of prostate cancer
New research has shown that immunotherapy can be effective in treating prostate cancer in men who are selected based on the genetic characteristics of their tumors.
Sep 16, 2024
0
0
